Deficiency of granulocyte-macrophage colony-stimulating factor (GM-CSF) in mice results in pulmonary alveolar proteinosis (PAP) from impaired surfactant catabolism by alveolar macrophages (AMs). Recently, we have shown that neutralizing anti-GM-CSF autoantibodies develop specifically in patients with idiopathic pulmonary alveolar proteinosis (iPAP). Analogous to murine PAP models, it is plausible that the autoantibodies reduce GM-CSF activity, resulting in AM dysfunction and surfactant accumulation. To examine this hypothesis, we estimated the neutralizing activity of the autoantibodies in the lungs of patients and characterized their biologic properties. GM-CSF bioactivity was completely abrogated in the bronchoalveolar lavage fluid (BALF) of patients with iPAP but not in healthy subjects. Autoantibodies were present in the alveoli in high concentrations and colocalized with GM-CSF. They recognized human GM-CSF with high avidity (K AV ‫؍‬ 20.0 ؎ 7.5 pM) and high specificity, reacting with its superstructure and neutralizing GM-CSF activity to a level 4000 to 58 000 times the levels of GM-CSF normally present in the lung. Although target epitopes varied among patients, GM-CSF amino acids 78 to 94 were consistently recognized. Thus, autoantibodies bind GM-CSF with high specificity and high affinity, exist abundantly in the lung, and effectively block GM-CSF binding to its receptor, inhibiting AM differentiation and function. Our data strengthen the evidence associating anti-GM-CSF autoantibodies with the pathogenesis of this disease.
Introduction
Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by the excessive accumulation of surfactant lipids and proteins in alveoli, resulting in impaired gas exchange and respiratory insufficiency. [1] [2] [3] Clinically, PAP is divided into congenital, secondary, and idiopathic forms, with the latter comprising more than 90% of cases. 2 Idiopathic PAP (iPAP) has a variable clinical course ranging from spontaneous remission to respiratory failure, and it can be complicated by secondary infections, frequently with opportunistic pathogens. 2 The pathogenesis of iPAP is unknown. However, the observation that histologically similar PAP occurs in mice genetically deficient in granulocyte macrophage-colony-stimulating factor (GM-CSF) (GM Ϫ/Ϫ mice) or its receptor (GM R␤c Ϫ/Ϫ mice) suggested that an abnormality in GM-CSF signaling may be involved. [4] [5] [6] [7] Clearance of surfactant lipids and surfactant proteins by alveolar macrophages (AMs) in these mice is severely impaired, thus providing an explanation for the increase in surfactant accumulation. 8 Murine PAP can be corrected by the local expression of GM-CSF in the lungs (GM Ϫ/Ϫ mice) [9] [10] [11] [12] or by bone marrow transplantation from a wild-type (GM R␤c Ϫ/Ϫ ) mouse. 13 AMs from GM Ϫ/Ϫ mice also display a number of molecular, morphologic, and functional abnormalities in addition to defective surfactant catabolism, all of which are corrected by the reconstitution of GM-CSF in the lungs. [9] [10] [11] 14, 15 AMs from GM Ϫ/Ϫ mice are deficient in the macrophage-differentiation-inducing transcription factor, PU.1: the presence and level of PU.1 in AMs is determined by the presence and level of GM-CSF in the lung. 12, 16, 17 Furthermore, retroviral-mediated PU.1 expression in cultured GM Ϫ/Ϫ AMs corrects all the observed AM defects described above, including surfactant protein catabolism. 12 These data show that GM-CSF exerts its critical role over surfactant homeostasis by acting locally in the murine lung and stimulating AM terminal differentiation. 12, [15] [16] [17] Several lines of evidence suggest that GM-CSF bioactivity in the lung is also critical for surfactant homeostasis in humans. First, the histopathologic abnormalities of the lung in iPAP in humans strongly resemble those of GM Ϫ/Ϫ mice. 1, [4] [5] [6] [7] 18, 19 Second, AMs in murine and human iPAP share a number of similar morphologic and functional abnormalities, including large "foamy" appearance, 4, 5, 18, 20 decreased phagocytosis, 14, 16, 18, 19, 21 and reduced cellular adherence. 14, 18 Third, bronchoalveolar lavage fluid (BALF) and sera from patients with iPAP contain polyclonal autoantibodies (hereafter referred to as autoantibodies) that bind and neutralize human GM-CSF. [22] [23] [24] Fourth, these autoantibodies are specific for iPAP and have not been detected in patients with congenital or secondary PAP, other lung diseases, or healthy persons. 22, 23 Because physiological levels of GM-CSF protein are normally low, including levels in the lungs that are on the order of several picograms per milliliter BALF, 25 the presence of neutralizing autoantibodies might have an important effect on GM-CSF bioactivity levels in the lung.
Based on these findings in animals and humans, we hypothesized that autoantibodies in iPAP bind and neutralize GM-CSF, thus producing a functional GM-CSF deficiency in the lungs. This reduces GM-CSF bioactivity in the lungs to levels below the threshold required for the maintenance of normal AM functions, including surfactant catabolism. To address this hypothesis, we established a GM-CSF bioassay and used this to measure GM-CSF bioactivity levels in the BALF of iPAP patients and controls and to evaluate the relationship between pulmonary autoantibody levels and GM-CSF bioactivity. In addition, the avidity and specificity of binding to GM-CSF, neutralizing capacity, and GM-CSF-binding epitopes were determined for autoantibodies from a number of iPAP patients. Results indicate that GM-CSF-neutralizing capacity in the lungs is in vast excess of pulmonary GM-CSF levels, demonstrating that anti-GM-CSF antibodies are functionally important in iPAP, where they eliminate GM-CSF activity and thus GM-CSF-dependent signaling in the lung.
Patients, materials, and methods

Study subjects
All clinical samples were collected from 7 hospitals in Japan participating in the study of iPAP after written, informed consent was obtained under protocols approved by the institutional review boards of the 7 participating hospitals. A diagnosis of iPAP was suspected from historical, physical, radiographic, and laboratory data and was confirmed by biochemical analysis of BALF, pulmonary histopathologic findings, or both. None of the iPAP patients had a history of intercurrent or antecedent illnesses associated with secondary PAP, 2 including hematologic disorders, infectious disease, or toxic pulmonary inhalation syndromes. None of the patients or subjects reported here have been included in prior reports on PAP from our group, and none had received treatment with exogenous GM-CSF. Sera were obtained from 107 patients with iPAP, 19 healthy control subjects, and 10 patients with other lung diseases (idiopathic pulmonary fibrosis [n ϭ 3], sarcoidosis [n ϭ 3], acute respiratory distress syndrome [n ϭ 2], collagen vascular disease [n ϭ 2]). BALF was obtained from 34 patients with iPAP, 18 healthy control subjects, and 14 patients with other lung diseases (eosinophilic pneumonia [n ϭ 4], idiopathic pulmonary fibrosis [n ϭ 4], sarcoidosis [n ϭ 3], hypersensitivity pneumonitis [n ϭ 2], eosinophilic granuloma [n ϭ 1]). Open-lung biopsy specimens were obtained from 4 patients with iPAP and 4 patients undergoing resection of surgically operable lung cancer.
Reagents
GM-CSFs.
The following recombinant GM-CSFs were kindly provided by the researchers or companies indicated: human (rhGM-CSF), Escherichia coli derived (Kirin Brewery, Takasaki, Japan), Chinese hamster ovary (CHO) cell derived (Novartis Pharma, Basel, Switzerland), yeast derived (Immunex, Seattle, WA); murine (Kirin Brewery); bovine (Dr Yuichi Yokomizo, National Institute of Animal Health, Tsukuba, Japan). Iodine-125 ( 125 I)-Bolton-Hunter-labeled rhGM-CSF (E coli derived) was purchased from NEN Life Science Products (Boston, MA). Recombinant carboxymethylated GM-CSF was produced according to the method described previously. 26 Trypsin-digested rhGM-CSF was prepared as described. 27 Other cytokines. Recombinant human interleukin-3 (IL-3), IL-4, IL-10, granulocyte colony-stimulating factor (G-CSF), macrophage colonystimulating factor (M-CSF), tumor necrosis factor-␣ (TNF-␣), and interferon-␥ (IFN-␥) were purchased from R&D Systems (Minneapolis, MN).
Antibodies. A polyclonal, epitope-specific, rabbit antihuman GM-CSF antibody was obtained after immunization with an rhGM-CSF peptide comprised of amino acid residues 54 to 73 and was purified by affinity chromatography. Epitope-specific murine antihuman GM-CSF monoclonal antibody sets 4117, 1089, 3092, and 1022, which recognize amino acid residues 1 to 11, 40 to 77, 78 to 94, and 110 to 127, respectively, of rhGM-CSF 28 were kindly provided by Dr Kanakura (Osaka University Medical School, Japan).
Cell line. A GM-CSF-dependent cell line, TF-1, 29 was kindly provided by Dr Kitamura (University of Tokyo, Japan).
Human alveolar macrophage cultures
Using flexible bronchoscopy, human AMs were obtained from iPAP patients and controls under conscious sedation and local anesthesia (lidocaine). Briefly, three 50-mL aliquots of normal saline were instilled and suctioned sequentially from the right middle lobe or lingula. Cells were enumerated by hemocytometer, cytocentrifuge sediments were prepared and stained with Diff-Quick, and differential cell counts were performed on 500 cells per person. AMs were isolated by adhesion to plastic culture dishes for 1 hour. Adherent cells were seeded into 96-well plates (5 ϫ 10 4 cells/well) in RPMI 1640 medium with or without 20% (vol/vol) cell-free BALF from either iPAP patients or healthy controls. In some experiments, the culture medium also contained rhGM-CSF (20 ng/mL). Cells were incubated for 14 days (37°C, 5% CO 2 ). Cell viability was measured by trypan blue dye exclusion, and cell growth was measured by the 3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide (MTT; SigmaAldrich, St Louis, MO) assay method, as described previously. 22, 30 Immunohistochemical localization of GM-CSF GM-CSF was localized in the lung by immunohistochemical staining on paraffin-embedded lung sections from 4 iPAP patients or 4 controls using a monoclonal murine antihuman GM-CSF antibody (R&D Systems), as described previously. 31 Control lung tissues were obtained from the normal lung parenchyma of surgical specimens removed for the resection of lung cancer nodules. Immunohistochemical staining for surfactant apoprotein A (SP-A) was used to identify alveolar type II cells using a murine antihuman SP-A antibody (DAKO, Carpinteria, CA) as above. Color development was performed using 3-amino-9-ethyl carbazole (AEC) liquid substrate chromogen (DAKO) for GM-CSF and diaminobenzidine (DAB) (Nichirei, Tokyo, Japan) for SP-A.
Quantification of GM-CSF bioactivity
TF-1 cells (2 ϫ 10 4 cells/well) were cultured (37°C, 5% CO 2 ) in microtiter plates for 3 days in macrophage-SFM medium (Invitrogen, Carlsbad, CA) containing rhGM-CSF in concentrations ranging from 0 to 20 ng/mL without or with BALF (20% vol/vol) from iPAP patients or healthy controls. TF-1 cell survival was evaluated using the MTT assay (SigmaAldrich) as described previously. 22, 30 The percentage of cell survival was calculated using the equation, cell survival (%) ϭ 100 ϫ (A Ϫ B)/(C Ϫ B), where A is the absorbance of TF-1 cells grown in the presence of rhGM-CSF and BALF, B is the absorbance of TF-1 cells grown in medium only, and C is the absorbance of TF-1 cells grown without BALF but containing GM-CSF (20 ng/mL). The concentration of exogenously added rhGM-CSF that was required for 50% survival of TF-1 cells (SC 50 , ng/mL) in each sample was determined. GM-CSF bioactivity was determined using the equation GM-CSF bioactivity ϭ SC 50 (C) Ϫ SC 50 (B), where GM-CSF bioactivity is expressed as nanogram equivalents of GM-CSF/mL BALF, SC 50 (C) is the concentration of exogenously added rhGM-CSF required for 50% survival of cells without added BALF, and SC 50 (B) is the concentration of exogenously added rhGM-CSF required for 50% survival of cells in the presence of BALF. Negative values for GM-CSF bioactivity in BALF are hereafter referred to as the neutralizing capacity of BALF.
Quantification and purification of anti-GM-CSF autoantibodies
Anti-GM-CSF autoantibodies (autoantibodies) were purified from the sera of iPAP patients as previously described. 32, 33 Antibody concentrations were measured in BALF or serum using purified autoantibodies as a standard, according to the method reported previously. 32, 33 
Confocal microscopy
Lung tissues resected from an iPAP patient or a healthy control were fixed in periodate-lysine-paraformaldehyde (PLP). 34 Sections were incubated in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA), immunostained with fluorescein isothiocyanate (FITC)-labeled antihuman immunoglobulin G (IgG; BD Biosciences, San Jose, CA) or with phycoerythrin (PE)-labeled GM-CSF (R&D Systems), and examined by confocal laser microscopy (Carl Zeiss, Tokyo, Japan). Serial sections from an iPAP patient was immunostained with FITC-labeled antimurine IgG (Nichirei) and PE-labeled G-CSF (R&D Systems) to exclude nonspecific binding. Hematoxylin-eosin was used for counterstaining.
GM-CSF autoantibody immune complexes
BALF from iPAP patients or healthy controls was delipidated with 1-butanol, and the protein fraction was precipitated with cold acetone. The protein pellet was resuspended in PBS, incubated with protein-A Sepharose 4 Fast Flow (Amersham Biosciences, Buckinghamshire, United Kingdom; 4°C, overnight), and washed with PBS/0.1% Tween 20. Bound proteins were eluted with glycine-HCl (100 mM, pH 2.7) and reprecipitated with 80% cold acetone. Bound and unbound protein fractions were size fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions and were transferred to polyvinylidene fluoride membranes (Millipore, Bedford, MA), and GM-CSF was detected using rabbit antihuman GM-CSF antibodies (1:1000; R&D Systems), horseradish peroxidase-conjugated goat antirabbit IgG antibodies (1:100; Nichirei), and ECL Plus (Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom).
Delipidated BALF proteins were subjected to PAGE under nonreducing conditions, followed by Western blot analysis as described. IgG in the BALF proteins was also detected by Western blot analysis using horseradish peroxidase-conjugated goat antihuman IgG (1:3000; DAKO) and ECL Plus.
BALF (100 L) from iPAP patients or healthy controls was incubated with [ 125 I]-GM-CSF (0.03 pmol; 2 hours, room temperature) and then subjected to PAGE under nonreducing conditions followed by autoradiography.
Characterization of autoantibodies
GM-CSF binding avidity and capacity of purified autoantibodies were determined using the [ 125 I]-GM-CSF binding assay method of Svenson et al. 35 Briefly, sera IgG from iPAP patients were isolated by protein-G Sepharose column chromatography (Amersham Biosciences) and quantified as described. Autoantibodies from each person were analyzed separately. Calculations were performed using molecular weights of 14.7 and 146 kDa for rhGM-CSF and IgG, respectively, and the results were expressed in picomolars. The binding capacity (B max , sites/mol IgG) was determined from the plateau value of the saturation-binding plot. The average affinity (K AV ) was defined as the concentration of free GM-CSF at 50% B max .
The binding specificity of autoantibodies for GM-CSF was determined using sandwich enzyme-linked immunosorbent assay (ELISA). Micro-ELISA plates (Nunc, Roskilde, Denmark) were coated with rhGM-CSF produced in E coli (as a standard) or GM-CSF produced in CHO cells, the large trypsin fragment of rhGM-CSF, carboxymethylated rhGM-CSF, murine or bovine GM-CSF, or various human cytokines (all at 1 g/mL) overnight, and then with 1% BSA/PBS. Plates were then incubated with purified autoantibody (100 ng/mL) for 1 hour. The reactivity of the autoantibodies in each well was measured by the method described above and was expressed as an OD ratio to that of E coli-derived rhGM-CSF.
The GM-CSF-neutralizing capacity of autoantibodies was determined as previously described using a bioassay based on GM-CSF-stimulated proliferation of TF-1 cells. 22, 30 Briefly, TF-1 cells (4 ϫ 10 4 cells/well) were cultured (37°C, humidified atmosphere, 5% CO 2 ) for 3 days in medium containing rhGM-CSF (5 ng/mL) and various concentrations of purified autoantibodies, murine antihuman GM-CSF monoclonal antibody (R&D Systems), goat antihuman GM-CSF polyclonal antibody (R&D Systems), or human IgG (Sigma-Aldrich). The percentage of growth inhibition was calculated from the following equation: Growth inhibition (%) ϭ 100 ϫ (A Ϫ B)/(A Ϫ C), where A, B, and C are the absorbances of TF-1 cells grown with rhGM-CSF (5 ng/mL) alone, rhGM-CSF and anti-GM-CSF antibodies or the negative control, and medium alone, respectively. The concentration of each autoantibody at 50% growth inhibition (IC 50 ) was obtained from each growth inhibition curve. GM-CSF epitope mapping of autoantibodies was performed using a competitive binding assay using murine monoclonal antibodies that recognize specific regions of human GM-CSF. 28 Purified autoantibodies (0-1 g/mL) were mixed individually with the murine monoclonal anti-GM-CSF epitope-specific antibodies 4117, 1089, 3092, and 1022 (each at 1 g/mL). These murine antibodies recognize rhGM-CSF residues 1-11, 40-77, 78-94, and 110-127, respectively. 28 Polyclonal rabbit anti-GM-CSF peptide 54-73 was used as a positive control, and human IgG (Sigma-Aldrich) was used as a negative control. Antibody mixtures were then incubated (4°C, overnight) in PBS containing 
Statistical analysis
Statistical analyses were performed on a microcomputer using StatView (version 4.0) (Abacus Concepts, Berkeley, CA) using the Mann-Whitney U test or the Kruskal-Wallis rank sum procedures for nonparametric data. P Ͻ .05 was considered significant.
Results
AM growth and development are inhibited by iPAP bALF
As shown in Table 1 , BALF from patients with iPAP contained fewer AMs and increased the number of lymphocytes compared with that from age-matched healthy subjects. AMs isolated from iPAP BALF by plastic adhesion had "monocyte-like" morphology and were smaller than those from healthy controls ( Figure 1A) . To determine whether an inhibitory activity for AM growth or function is present in the iPAP lung, we incubated AMs from iPAP patients in the presence of culture medium alone or medium plus iPAP-or control-BALF in the absence or presence of GM-CSF (20 ng/mL). AMs from iPAP patients were viable but remained small after 14 days in culture with medium alone or in medium containing iPAP-BALF ( Figure 1B) . In contrast, iPAP-AMs developed a normal appearance and were larger in medium containing normal
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BALF with or without added GM-CSF. Although iPAP-AMs failed to grow and develop a normal appearance in medium plus iPAP-BALF, they did so when additional GM-CSF (20 ng/mL) was added. The effects of control-BALF or GM-CSF on iPAP-AM growth were confirmed with an MTT assay (data not shown). Cell viability in each instance was greater than 90%. These data establish that GM-CSF bioactivity is reduced in the iPAP-BALF by an inhibitory substance that can be overcome with the addition of GM-CSF.
Pulmonary GM-CSF expression is not diminished in iPAP
Functional GM-CSF activity appeared to be absent in BALF from iPAP patients, but it could be restored with the addition of large amounts of GM-CSF to medium containing iPAP BALF. Therefore, we evaluated GM-CSF levels in lung tissues from 4 iPAP patients and 4 controls using an immunohistochemical approach. Epithelial cells projecting into the alveolar lumen were strongly stained with anti-GM-CSF antibody in iPAP and control lungs ( Figure 2 ). These cells were also stained with anti-SP-A antibody, establishing that they are alveolar type 2 epithelial cells. The proportion of alveolar epithelial cells showing GM-CSF expression was evaluated by immunohistochemistry, with similar percentages found for iPAP patients (n ϭ 4; 50.5% Ϯ 8.4%) and controls (n ϭ 4; 40.8% Ϯ 5.0%) (P ϭ .08). Thus, GM-CSF protein production in the lungs of iPAP patients does not appear to be reduced compared with normal lungs.
GM-CSF bioactivity is reduced in the lungs of iPAP
Discordance between the physical presence and functional activity of GM-CSF was apparent in the BALF of iPAP patients but not in controls. Therefore, we measured the bioactivity of GM-CSF in BALF using a bioassay based on GM-CSF-dependent growth stimulation of TF-1 cells. 22, 30 Increasing concentrations of GM-CSF stimulated an increasing proliferation of TF-1 cells, reaching a maximum at very low doses on the order of 2 to 3 ng/mL ( Figure  3A ). Adding BALF from healthy controls (n ϭ 6; 20% vol/vol) had no effect on the survival of TF-1 cells at equivalent doses of exogenous GM-CSF, suggesting that neither large amounts of GM-CSF nor GM-CSF inhibitory activity was present ( Figure 3B ). In contrast, adding BALF from iPAP patients (n ϭ 8; 20% vol/vol) shifted the viability curve significantly to the right, demonstrating the presence of a potent GM-CSF-inhibitory activity ( Figure 3B) . Importantly, the GM-CSF-inhibitory activity was reversible as maximum survival was achieved with high doses of exogenous GM-CSF (20 ng/mL). GM-CSF bioactivity in BALF was Ϫ24.9 Ϯ 16.4 ng/mL (median, Ϫ23.3; range, Ϫ57.5 to Ϫ4.3) for iPAP and 0.017 Ϯ 0.387 ng/mL (median, Ϫ0.126; range, Ϫ0.34 to 0.63) for healthy controls ( Figure 3C ). We also determined GM-CSF levels in control BALF to be 1.07 Ϯ 0.16 pg/mL (range, 0.88-1.28) using an ELISA system (AN'ALYSA; R&D Systems), so GM-CSF-neutralizing capacity in iPAP-BALF was present in vast excess over the levels of GM-CSF normally present within the lung.
Autoantibodies occur at high levels in patients with iPAP
We sought to extend and quantify our observation regarding the presence of autoantibodies (anti-GM-CSF autoantibodies) in iPAP For personal use only. on January 8, 2018. by guest www.bloodjournal.org From in a large cohort. Therefore, the levels of autoantibodies were quantified by ELISA in the BALF and sera of patients with iPAP or other lung disorders and in healthy controls. BALF and sera of iPAP patients contained high concentrations of autoantibodies (median, 1.15; range, 0.09-5.40 g/mL in BALF [n ϭ 34]; median, 88.6; range, 16.6-470 g/mL in sera [n ϭ 107], respectively) in contrast to healthy controls and patients with other lung diseases that were all under the detection limit (0.05 g/mL for BALF and 3 g/mL for serum) ( Table 2 ). Thus, autoantibody levels are high in the lungs and sera of patients with iPAP and are specific for this disorder. 1-2), iPAP patient (lanes 3-4) , or, as a control, purified yeast-derived rhGM-CSF (lane 5). Bound and unbound fractions (indicated) were separated and subjected to SDS-PAGE under reducing conditions and Western blotting using a rabbit anti-GM-CSF antibody. Under these conditions, the rhGM-CSF standard consists of 3 molecular species migrating at 19.5, 16.8, and 15.5 kDa. (B) Detection of GM-CSF and IgG in BALF by Western blotting. BALF from a healthy control (lanes 2, 4), iPAP patient (lanes 3, 5) , or rhGM-CSF (lane 1) was subjected to native PAGE and then Western blotting using a rabbit anti-GM-CSF antibody (lanes 1-3) Numbers in parentheses are ranges. *Concentrations of autoantibodies in BALF and serum were all under the detection limit (0.05 g/mL in BALF; 3 g/mL in serum).
Localization of free autoantibodies in the lung of iPAP patients
To demonstrate that GM-CSF-binding activity colocalized with immunoglobulin molecules in the lungs of iPAP patients, immunohistochemical staining was carried out with PEconjugated GM-CSF and FITC-conjugated anti-IgG. By confocal microscopy, GM-CSF-binding activity and IgG were readily detected and demonstrated strong colocalization in the iPAP lung ( Figure 4A-D) . Nonspecific binding of PE-or FITCconjugated proteins on the intra-alveolar material was ruled out by staining of the serial sections with FITC-conjugated antimurine-IgG and PE-conjugated human G-CSF ( Figure 4E-H) . The lungs of healthy controls had detectable, but vastly reduced, amounts of IgG, minimal or no GM-CSF-binding activity, and no colocalization ( Figure 4I-L) .
Autoantibodies form immune complexes in the lungs of iPAP patients
We next sought evidence of immune complexes containing GM-CSF by immunoprecipitation from BALF using protein-A Sepharose beads followed by Western blotting to detect GM-CSF. GM-CSF was detected in iPAP-BALF in the protein-A bound, but not unbound, fraction, consistent with the presence of GM-CSF bound to IgG ( Figure 5A ). GM-CSF was not detected in either fraction in BALF from healthy controls. When the BALF protein was evaluated by native gel electrophoresis and Western blotting, GM-CSF was also detected as a broad high-molecular-weight smear that coincided with a similar smear detected by blotting for IgG ( Figure 5B) . Using yet another approach, a "supershift" of GM-CSF was seen after incubation of [ 125 I]-GM-CSF with iPAP-BALF but not with control-BALF ( Figure 5C ). Using several distinct experimental approaches, these data strongly support the notion that GM-CSF exists in the form of immune complexes in the lungs of iPAP patients.
Autoantibodies bind GM-CSF with high avidity and specificity
The absence of detectable GM-CSF bioactivity in BALF from iPAP patients suggested that the binding affinity of autoantibodies for GM-CSF might be sufficient to effectively compete for the binding of GM-CSF to its receptor. Thus, autoantibody binding avidity and capacity was determined by saturation-binding analysis using purified autoantibodies and [ 125 I]-GM-CSF ( Figure 6A ). Autoantibodies purified from 11 iPAP patients had a similar, high avidity (19.96 Ϯ 7.54 pM) in contrast to that of a commercial goat polyclonal antibody (275.4 pM) ( Table 3 ). The binding capacity of autoantibodies from a range of iPAP patients was similar, with 0.24 Ϯ 0.13 sites/mol IgG, indicating that 1.8 to 7.8 autoantibody molecules bound each molecule of GM-CSF (Table 3) . Consistent with these avidity data, the autoantibodies exhibited strong neutralizing capacity. The mean neutralizing capacity of autoantibodies was 10-to 500-fold greater than those of the commercial neutralizing polyclonal or monoclonal antibodies tested, respectively (Table 3 ). For personal use only. on January 8, 2018. by guest www.bloodjournal.org From
The binding of autoantibodies to GM-CSF was also specific. Purified autoantibodies from 12 iPAP patients showed similar binding to rhGM-CSF prepared in E coli (nonglycosylated) and CHO cells (glycosylated), indicating the carbohydrate moiety was not involved in binding ( Figure 6B ). Autoantibodies did not bind GM-CSF that had been carboxymethylated (which disrupts disulfide bonds), suggesting that a secondary or tertiary structure may be recognized. Autoantibodies did not bind GM-CSF after trypsin cleavage, which retains the 2 disulfide bonds but not peptides 1 to 30, 59 to 85, and 108 to 111, suggesting that these peptides may contain critical binding epitopes ( Figure  6B ). Autoantibodies bound bovine GM-CSF, which has 68% amino acid homology with human GM-CSF, but not murine GM-CSF, which has only 53% homology ( Figure 6C ). None of a large variety of cytokines tested was bound by autoantibodies ( Figure 6D ). These findings demonstrate that autoantibodies consistently bind GM-CSF with high avidity and specificity and likely recognize a secondary or tertiary, nonglycosylated portion of the molecule.
Autoantibodies target a functional domain of GM-CSF
The specific epitopes on GM-CSF recognized by autoantibodies were identified using a competitive binding assay with [ 125 I]-GM-CSF and 4 different epitope-specific murine monoclonal antibodies ( Figure 7A ). Monoclonal antibodies recognizing GM-CSF amino acids 1 to 11, 40 to 77, and 110 to 127 exhibited variable fractional inhibition by autoantibodies from separate patients ( Figure 7B ). In contrast, the monoclonal antibody recognizing GM-CSF residues 78 to 94 was consistently and strongly inhibited by autoantibodies from all patients, with a mean percentage inhibition of 78.97% Ϯ 11.71% ( Figure 7B ). This epitope has been reported to be an important functional domain of GM-CSF. 27, 28, 36, 37 Thus, though autoantibodies can recognize various regions of the GM-CSF molecule, the consistent, strong targeting of an epitope known to be important for GM-CSF function strongly supports the notion that autoantibodies specifically neutralize GM-CSF in patients with iPAP.
Discussion
The present study was designed to determine the functional significance of autoantibodies in patients with iPAP and to characterize their specific molecular interactions with GM-CSF. Results demonstrate that BALF from iPAP patients strongly inhibited AM growth and development in contrast to BALF from healthy controls. This effect was caused by IgG in iPAP patients that bound GM-CSF with high avidity. GM-CSF was readily detected by immunohistochemistry in the lungs of iPAP patients. However, neutralizing capacity by the autoantibodies was in nanogram per milliliter order, which far exceeds the concentration of GM-CSF in BALF from healthy lung (ie, picogram per milliliter order). This "deficit" of GM-CSF could be overcome by the addition of excess GM-CSF, demonstrating that the neutralizing capacity was saturable. Autoantibodies colocalized with GM-CSF-binding activity in the lungs of iPAP patients. GM-CSF-autoantibody complexes were also demonstrated in BALF from iPAP patients by immunoprecipitation and Western blotting. Finally, epitope mapping demonstrated that most patients with iPAP had autoantibodies with epitopes targeting a region of GM-CSF within amino acids 78 to 94, an important functional domain. Together these data demonstrate that the neutralizing anti-GM-CSF autoantibodies in iPAP patients are functionally significant and severely impair pulmonary GM-CSF bioactivity, likely impairing the development of AM terminal maturation.
Characterization of neutralizing anti-GM-CSF autoantibodies in iPAP
Autoantibody levels were surprisingly high in most iPAP patients. Although the reasons for this are unclear, the use of a highly purified autoantibody as a standard for ELISA ensured the accuracy of these findings. One possible explanation is that an "immunologic stimulus" is continuously present in the lung or elsewhere. Improving pulmonary functions after therapeutic whole lung lavage may support this idea because it may remove such stimulus. 2 Autoantibodies bound GM-CSF with high avidity, which was far higher than that of commercially Percentage of inhibition for the reactions without the autoantibodies and without monoclonal antibody was defined as 0% and 100% inhibition, respectively. Control human IgG and rabbit anti-GM-CSF peptide 54-73 polyclonal antibodies were used for negative and positive controls, respectively. Distribution of the percentage of inhibition was variable among the patients, but the autoantibodies consistently and strongly inhibited GM-CSF binding to the monoclonal antibody 3092.
